The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19 when administered within the first week of their symptoms.
As reported in an Original Research article published by the NEJM on August 18, 2021, the trial was stopped in February 2021 due to a lack of efficacy based on a planned interim analysis.
Read More
